Serious adverse events · adults with Raynaud's phenomenon (primary or secondary)
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Serious adverse eventsd · adults with low back pain
1 finding from 1 review
Serious adverse events · Ménière’s disease
It is very uncertain whether betahistine changes serious adverse events compared with placebo/no treatment (very low certainty).
1 finding from 1 review
Serious adverse events · people with vestibular migraine
It is very uncertain whether beta‐blockers changes serious adverse events compared with placebo (very low certainty).
1 finding from 1 review
Serious adverse events · adults with PPPD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · Ménière’s disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · Ménière’s disease
It is very uncertain whether intratympanic corticosteroids changes serious adverse events compared with placebo/no treatment (very low certainty).
1 finding from 1 review
Serious adverse events · Ménière’s disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · Ménière’s disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · Ménière’s disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · adults with vestibular migraine
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · adults with acute attacks of vestibular migraine
1 finding from 1 review
Serious adverse events · adults with PPPD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · adults with PPPD
1 finding from 1 review
Serious adverse events · adults with PPPD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · pPostmenopausal women at higher risk of fractures1
Risedronate 5 mg/day showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
RR 1 [0.94, 1.07]
Studies not reported
Moderate
Serious adverse events · postmenopausal women at lower risk of fractures1
It is very uncertain whether risedronate 5 mg/day changes serious adverse events compared with placebo (very low certainty).
1 finding from 1 review
RR 0.74 [0.42, 1.3]
Studies not reported
Very low
Serious adverse events · people with cancer and receiving palliative care with opioid‐induced bowel dysfunction
1 finding from 1 review
Serious adverse eventsi · people receiving palliative care irrespective of whether they had cancer with opioid‐induced bowel dysfunction
Methylnaltrexone may leads to lower serious adverse eventsi compared with placebo (low certainty).
1 finding from 1 review
Serious adverse eventsh · people with cancer irrespective of whether receiving palliative care and with opioid‐induced bowel dysfunction
Naldemedine showed no clear difference in serious adverse eventsh compared with placebo (low certainty).
1 finding from 1 review